Tramadol Hydrochloride Tablet, Coated
Product Images NDC 0904-7496

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 0904-7496). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

50mg Carton Label (6b0b95b2 Ae4c 42e8 9f2e Bcdaffda62e2 00)

50mg Carton Label (6b0b95b2 Ae4c 42e8 9f2e Bcdaffda62e2 00)
This is a description of a medication package for Tramadol Hydrochloride tablets. The package contains 100 tablets, with each tablet containing Tramadol Hydrochloride, USP 50mg. It is important to store the tablets at 20°C to 25°C (68°F to 77°F) and keep them in a tight container as per USP guidelines. The medication should be dispensed with a Medication Guide, and it is recommended to follow the usual dosage instructions provided in the product insert. The package is marked for institutional use only and is not child-resistant.*
FDA Label Image

1 (Tramadol Hydrochloride Tablets Usp 50 mg 1)

FDA Label Image

1 (Tramadol Hydrochloride Tablets Usp 50 mg 2)

1 (Tramadol Hydrochloride Tablets Usp 50 mg 2)
This text appears to show concentration levels in nanograms per milliliter (ng/mL), specifically for Tramadol and its metabolite M1. The values provided are for multiple doses and single doses of the substances. It seems to be a table or data related to the analysis of the concentration of these compounds in a sample.*
FDA Label Image

1 (Tramadol Hydrochloride Tablets Usp 50 mg 3)

1 (Tramadol Hydrochloride Tablets Usp 50 mg 3)
This is a report on the discontinuation rates related to nausea and vomiting in a clinical trial with protocol CAPSS-047. The data shows that 8% of participants discontinued the treatment due to these side effects within 10 days of taking 200 mg/day dosage. The study was likely double-blind and lasted at least 25 days.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.